Skip to main content

Heather Wakelee

Dr Heather Wakelee is a Professor of Medicine and Chief of the Division of Oncology at Stanford University, Deputy Director of the Stanford Cancer Institute, and Interim Medical Director of the Stanford Cancer Center. She is a graduate of Princeton University and Johns Hopkins University School of Medicine and completed her postgraduate training at Stanford University. 

Dr Wakelee has authored or co-authored over 200 medical articles on lung cancer and thymic malignancies and is involved in dozens of clinical trials. Her research focuses on many specific lung cancer subtypes defined by specific mutations in EGFR, ALK, ROS1, RET, BRAF, and others. Additionally, she focuses on perioperative therapy of lung cancer including leading many trials in this area, such as the pivotal Impower010 study of the adjuvant immunotherapy agent atezolizumab, which set a new standard of care for resected early stage NSCLC. She is also engaged in collaborations with colleagues focused on biomarkers and population science research.  Dr Wakelee is the President of the International Association for the Study of Lung Cancer (IASLC); an executive committee member of the ECOG-ACRIN Cancer Research Group; and she is a Fellow of the American Society of Clinical Oncology (FASCO).  She is passionate about mentorship and is proud of the many former trainees who are now working as lung cancer investigators and care providers.


Latest contributions from Heather Wakelee

Nasser Altorki, Heather Wakelee

13-04-2022 | Non-small-cell lung cancer | Video

PD-L1 expression in early NSCLC: Interpreting the data so far

Heather Wakelee and Nasser Altorki discuss the current position on PD-L1 expression and immune checkpoint inhibition in early-stage, resectable NSCLC.